COMMUNIQUÉS West-GlobeNewswire

Nicox's Shareholder Letter
22/03/2024
Dear Shareholder, The upcoming Extraordinary General Meeting, which will take place on April 10, is of particular importance for Nicox. I am writing to you today, in my capacity as the new Chief Executive Officer, in [...]
Nicox - Lettre aux Actionnaires
22/03/2024
Madame, Monsieur, Cher Actionnaire, L’Assemblée générale ordinaire et extraordinaire convoquée pour le 10 avril prochain est d’une importance particulière pour Nicox. Je vous écris aujourd'hui en ma qualité de nouveau [...]
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
22/03/2024
Availability of the Q1 2024 Memorandum for modelling purposes Paris, France – March 22, 2024 . Sanofi announced today that its Q1 2024 Memorandum for modelling purposes is available on the "Investors" page of the [...]
Communiqué de presse : Mise en ligne du document «Q1 2024 Memorandum for modelling purposes»
22/03/2024
Mise en ligne du document «Q1 2024 Memorandum for modelling purposes» Paris, France, le 22 mars 2024 . Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « [...]
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US
22/03/2024
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a clinical-stage biotech company [...]
Idorsia thanks Guy Braunstein for his years of service as he retires
22/03/2024
Guy Braunstein, currently Chief Medical Officer and member of the Idorsia Executive Committee, to retire at the end of March 2024 Allschwil, Switzerland – March 22, 2024 Idorsia Ltd (SIX: IDIA) today announced that Guy [...]
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
22/03/2024
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point Transaction is expected to be accretive to 2024 earnings Estimated peak sales [...]
UCB Convening Notice to the General Meeting of the Shareholders 2024
22/03/2024
CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders for the ordinary and extraordinary general meeting of the shareholders (the “ General Meeting ” or the “ GM ”) [...]
UCB Convocation à l'Assemblée Générale des Actionnaires 2024
22/03/2024
CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES Le Conseil d’administration invite les actionnaires à l’assemblée générale ordinaire et extraordinaire des actionnaires (« l’Assemblée Générale » ou « l’AG »)) qui se [...]
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
22/03/2024
SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has [...]
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
22/03/2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the registration stage of [...]
Theratechnologies Appoints Jordan Zwick to its Board of Directors
22/03/2024
MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of [...]
Theratechnologies nomme Jordan Zwick à son conseil d’administration
22/03/2024
MONTRÉAL, 21 mars 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique axée sur la mise au point et la commercialisation de [...]
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
22/03/2024
WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD [...]
VitalHub Corp. Reports Fourth Quarter and Year-End 2023 Results
21/03/2024
TORONTO, March 21, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) announced today it has filed its Consolidated Financial Statements and Management's Discussion and [...]
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
21/03/2024
Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone’s novel Selected TIL programs for solid tumors presented at SITC 2023 [...]
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
21/03/2024
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and [...]
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
21/03/2024
LAWRENCEVILLE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces [...]
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
21/03/2024
REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117 [...]

Pages